// App-Quantinova.ai

e16561 : Real-world treatment patterns and overall survival in previously treated advanced renal cell carcinoma patients receiving nivolumab in the UK.

Researchers

Presenter

  • Tom Waddell

Principal Investigators

  • Kate Fife

  • Richard Griffiths

  • Anand Sharma

  • Poonam Dhokia

  • Jason Gordon

  • Lara Groves

  • Michael Hurst

  • Daniel Sugrue

  • Carmen Tsang

  • Stephen Mckenna

  • John Houghton

  • Robert Carroll

Medical Centers

  • The Christie NHS Foundation TRUST, Manchester, United Kingdom

  • NIHR Cambridge Biomedical Research Centre, Cambridge, United Kingdom

  • The Clatterbridge Cancer Centre, Liverpool and Wirral, United Kingdom

  • Mount Vernon Cancer Centre, Northwood, United Kingdom

  • Bristol-Myers Squibb Pharmaceuticals Ltd, Uxbridge, United Kingdom

  • Health Economics & Outcomes Research Ltd, Birmingham, United Kingdom

  • Health Economics & Outcomes Research Ltd, Birmingham, United Kingdom

  • (HEOR) Ltd, Health Economics and Outcomes Research, Cardiff, United Kingdom

  • Bristol-Myers Squibb Pharmaceuticals Ltd, Uxbridge, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

  • Oncology (ONC)

Disease

  • Metastatic Renal Cell Cancer

Biomarkers

  • N/A

Drug/Treatment

  • Nivolumab

Outcome

  • N/A

Study Design

  • Multicenteric

  • Cohort

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved